- Home
- Equipment
- north america
- haematopoietic stem cells
Show results for
Refine by
Haematopoietic Stem Cells Equipment Supplied In North America
77 equipment items found
by:ABEC, INC. based inBethlehem, PENNSYLVANIA (USA)
Our conditionally-immortalized allogeneic cell lines are derived from hematopoietic stem cells and allows us to eliminate the need for recurring donors. From a single cell line, we can produce unlimited quantities of consistent fully-functional cells with targeted ...
Manufactured by:Editas Medicine based inCambridge, MASSACHUSETTS (USA)
We are pursuing a number of diseases using an in vivo editing approach, focusing on hematopoietic stem cells and other tissue types, and we are excited about the progress we’ve ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a+ CD8+ T Cells, PD-1+CD8+ T Cells, TIM-3+CD8+ T Cells ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Hemoglobinopathies: Sickle cell disease, ...
Manufactured by:Profacgen based inShirley, NEW YORK (USA)
Recombinant Cynomolgus PDCD1 Protein (B0LAJ3) (Leu 25 - Gln 167) with a polyhistidine tag at the C-terminus was expressed in ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
The LVV platform is ideal for modifying hematopoietic stem cells (HSCs) to address disorders affecting the bone marrow. The LVV transduction process occurs ex vivo (outside the body), which ensures that the gene has been properly integrated before the therapy is given to the patient. The process involves collection and isolation of a patient’s hematopoietic stem cells ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Our first multi-targeted Treatment System is comprised of VOR33-CLL1 multiplex-edited eHSC therapy and VCAR33-CLL1 multi-specific CAR-T therapy. Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic stem cells may represent ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
The LVV platform is ideal for modifying hematopoietic stem cells (HSCs) to address disorders affecting the bone marrow. The LVV transduction process occurs ex vivo (outside the body), which ensures that the gene has been properly integrated before the therapy is given to the patient. The process involves collection and isolation of a patient’s hematopoietic stem cells ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
In order to obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, Hemogenyx Pharmaceuticals developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. CDX antibodies belong to a class of bi-specific antibodies that redirect patients’ ...
Manufactured by:Protein Foundry LLC. based inWest Allis, WISCONSIN (USA)
Human CXCL2 is a 73 amino acid, ELR+ chemokine that belongs to the GRO isoform subset which activates the G protein-coupled receptors CXCR2. LPS-stimulated macrophages strongly express CXCL2 in addition to the constitutive expression by macrophages. CXCL1 is a potent chemoattractant for neutrophils and hematopoietic stem cells and an activator of basophils. ...
Manufactured by:Access Biologicals LLC based inVista, CALIFORNIA (USA)
Suitable for culturing neuronal cells & hematopoietic stem cells; Collected from controlled donor herds in the US; .2 micron filtered; mycoplasma, 9CFR113.53 & virus ...
Manufactured by:Caprico Biotechnologies, Inc. (CBI) based inNorcross, GEORGIA (US) (USA)
Clone APN1464 recognizes cell surface CD13 antigen, a 150kDa membrane glycoprotein. The CD13 antigen is highly expressed mostly on myeloid-derived hematopoietic cells including granulocytes, monocytes, mast cells, and GM-progenitor cells. CD13 abundantly expresses on most of the malignant cells of myeloid origin such as AML, CML and also on smaller subset of cancer cells of lymphoid origin. ...
Manufactured by:ACROBiosystems based inNewark, DELAWARE (USA)
Interleukin-21 (IL-21) is a secreted protein which belongs to the IL-15 / IL-21 family. Interleukin-21 / IL-21 belongs to a family of cytokines that bind to a composite receptor consisting of a private receptor (IL21R) and the common cytokine receptor gamma chain (gamma(C)). Interleukin-21 / IL-21 impacts a number of cell types, including CD8+ memory T cells, NK cells and subsets of CD4 memory T ...
Manufactured by:Sartorius CellGenix GmbH based inFreiburg, GERMANY
CellGenix Recombinant Human Flt-3L reliably supports the proliferation of hematopoietic stem cells (HSCs). CellGenix® rh Flt-3L is produced in our dedicated animal-free GMP facility ensuring maximum safety for optimal use in ATMP ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
FA is a rare, genetic disorder affecting DNA repair. Approximately two-thirds of FA cases are caused by genetic defects in the FANCA gene, which results in the FA subtype known as FA Complementation Group A (FA-A). FA patients may develop bone marrow failure (very low blood counts), cancers of the blood or other ...
by:Precipio, Inc based inNew Haven, CONNECTICUT (USA)
IV-Cell universal culture media is a Research-use only (RUO), ready-to-use, fully supplemented medium developed specifically to support bone marrow and peripheral blood cell culture for in vitro cytogenetic analysis of hematological disease. IV-Cell is a proprietary culture media that does not require the addition of any mitogens. Additionally, it enables simultaneous culturing of all four (4) ...
Manufactured by:Trailhead Biosystems Inc. based inBeachwood, OHIO (USA)
We are developing human long-term hematopoietic stem cells (LT-HSCs) from human (non-embryo) induced pluripotent stem cells (iPSCs). HSCs are rare subsets of hematopoietic cells that are responsible for the life-long production of all blood cell lineages, and for the reconstitution of bone marrow (BM) after transplantation into myeloablative recipients. We will use our LT-HSCs cells as the ...
Manufactured by:AllCells based inAlameda, CALIFORNIA (USA)
Mobilized Leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate the migration of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow niche into the circulation. Mobilized peripheral blood, enriched in single-donor CD34+ HSPCs is collected through leukapheresis using the Spectra Optia® Apheresis System’s ...
Manufactured by:Rocket Pharmaceuticals, Inc. based inCranbury, NEW JERSEY (USA)
PKD is a rare, genetic blood disorder. PKD is caused by a defect in the PKLR gene which is responsible for energy production in red blood cells (RBCs). RBCs carry oxygen to the rest of the body. When the PKLR gene has a defect, RBCs are limited in their ability to produce energy and remain intact. As a result, patients with PKD frequently have anemia, chronic fatigue, yellowing of the skin and ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
CYNK-CAR candidates are being developed as allogeneic, off-the-shelf approaches through gene modification of human placental hematopoietic stem cell-derived natural killer (NK) cells. Various CAR constructs against hematological and solid tumor targets are under pre-clinical ...